A prospective trial engaging a radiopharmaceutical switch maintenance approach like in Figure 1 using a 212Pb-TCMC-trastuzumab immunoconjugate enrolling women with recurrent or refractory HER2-avid ovarian carcinoma might be of future interest. Here, ERBB2 is linked to ovarian carcinoma.